This guidance applies to clinical trials that will be conducted under an investigational new drug application (IND), including such clinical trials (e.g., research or academic studies) that are not intended to support marketing applications. The principles in this guidance are intended to
support the ethical conduct of clinical trials as well as to ensure the integrity of the trial and the reliability of the results.